Emerging peptide · Mid-stage emerging

ACE-031

Soluble ActRIIB-Fc decoy receptor — Acceleron's myostatin-pathway program halted in DMD over vascular safety signals.

Phase 2 (halted)

Investigational compounds — read carefully

This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.

Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.

At a glance

An engineered fusion of activin receptor type IIB extracellular domain with an antibody Fc region designed to act as a circulating decoy that sponges myostatin and related ligands. Phase 2 trials in Duchenne muscular dystrophy were stopped over nosebleed and gum-bleeding signals.

Class
Soluble ActRIIB-Fc decoy receptor
Sponsor
Acceleron Pharma
Stage
Phase 2 (halted)
Lead use case
Duchenne muscular dystrophy (DMD)

What it is

ACE-031 is an engineered protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) fused to an immunoglobulin Fc region. The construct was designed to circulate as a decoy receptor that binds and sequesters myostatin and related TGF-β family ligands before they can engage native receptors on muscle cells, thereby relieving suppression of muscle growth.

Current research status

Acceleron Pharma advanced ACE-031 into Phase 2 trials in pediatric Duchenne muscular dystrophy patients. The program was halted in 2013 after safety signals — most prominently epistaxis (nosebleeds) and gingival bleeding — emerged in trial participants. The trial was paused, then ultimately discontinued. Acceleron subsequently shifted resources toward sotatercept and other selective TGF-β superfamily programs.

Mechanistic rationale

Myostatin (GDF-8), activin A, GDF11, and several BMPs all signal through ActRIIB. ACE-031's design — a soluble form of the receptor's ligand-binding domain — was intended to act as a broad-spectrum decoy: bind multiple ligands simultaneously and prevent receptor activation. The breadth of ligand binding is both the strategic strength (potentially additive blockade of muscle-suppressive signals) and the source of off-target liability (the same pathway regulates vascular and erythroid biology).

Available evidence

Phase 1 healthy-volunteer studies (Attie et al., Muscle Nerve 2013) — Single-dose ACE-031 produced increases in lean mass and modest changes in markers of muscle metabolism in healthy postmenopausal women, supporting target engagement.[1]

Phase 2 DMD trial (halted) — Pediatric DMD patients received subcutaneous ACE-031 at multiple dose levels. Early signals of functional benefit were promising, but the trial was halted due to vascular adverse events (epistaxis and gum bleeding) before efficacy could be definitively established.[2]

Why it's interesting

ACE-031 is a foundational data point in the modern myostatin-pathway story. The trial halt was an early lesson that broad ActRIIB blockade engages ligands beyond myostatin — the vascular bleeding signal ultimately traced to off-target effects on related TGF-β family pathways (BMP9/10) involved in vascular integrity. That lesson directly motivated the more selective programs that followed: apitegromab (selective for latent myostatin), trevogrumab (selective ligand binding), and bimagrumab (receptor blockade with a different selectivity profile). For users following the myostatin-inhibitor space, ACE-031 is the discontinued precursor whose failure shaped what came next.

Limitations & risks

The development program was halted on safety grounds; the molecule itself is not in active development. Anyone encountering ACE-031 in non-research contexts (e.g., grey-market vendors) would be obtaining material with a known halted-for-safety history. The molecule's failure does not invalidate the broader myostatin-blockade strategy — but it does establish that pan-ligand ActRIIB decoys carry vascular liability that selective programs are specifically designed to avoid.

Community discussion notes

ACE-031 occupies an important position in fitness-community discussions of myostatin inhibitors as a cautionary historical example. The compound is sometimes referenced in the same conversations as YK-11 and follistatin — but ACE-031 is a discontinued biologic, not an actively developed or commercially available compound, and its safety history is part of the package.

The takeaway

ACE-031 is a halted Phase 2 program whose primary contemporary value is historical and educational. The trial halt established the importance of selectivity in myostatin-pathway inhibition and shaped every program that followed. Active development resides with the more selective successors (apitegromab, trevogrumab, bimagrumab) rather than ACE-031 itself.

References

  1. Attie KM, et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013;47(3):416-423. https://pubmed.ncbi.nlm.nih.gov/23169607/
  2. Campbell C, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55(4):458-464. https://pubmed.ncbi.nlm.nih.gov/27462804/
  3. Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Invest. 2021;131(9):e148372. https://pubmed.ncbi.nlm.nih.gov/33938454/